OSAKA, Japan and CAMBRIDGE, Massachusetts, June 9, 2026
Takeda has reached a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) accepting for review its supplemental Biologics License Application (sBLA) for intravenous ENTYVIO® (vedolizumab) in pediatric patients aged two years and older with moderately to severely active ulcerative colitis (UC) and Crohn’s disease. If approved, ENTYVIO would become the first and only gut-focused biologic therapy specifically indicated for pediatric patients in this age group, addressing a major unmet need in inflammatory bowel disease (IBD) treatment. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date in the first quarter of 2027, bringing the therapy one step closer to expanding treatment options for children and adolescents living with chronic gastrointestinal inflammatory diseases. The regulatory submission underscores Takeda’s commitment to advancing evidence-based therapies for vulnerable patient populations and strengthening its leadership position in gastrointestinal and inflammatory disease care.
ENTYVIO Could Address Critical Gaps in Pediatric IBD Care
Inflammatory bowel disease remains one of the most challenging chronic conditions affecting children and adolescents, with approximately 25% of IBD cases diagnosed before the age of 20. Pediatric patients frequently experience more extensive and aggressive disease progression than adults, often requiring lifelong treatment and monitoring. Despite advances in biologic therapies, treatment options specifically approved for young patients remain limited. Takeda’s ENTYVIO is a gut-selective biologic therapy that works by targeting the α4β7 integrin pathway, reducing inflammatory cell migration into gastrointestinal tissues while limiting systemic immune suppression. The therapy has already established a strong clinical profile in adults with ulcerative colitis and Crohn’s disease through more than a decade of clinical research and real-world experience.
If approved for pediatric use, ENTYVIO could provide physicians with a highly targeted treatment option designed to achieve and maintain disease remission while addressing the unique needs of younger patients facing decades of disease management ahead. The potential approval also reflects increasing efforts within the pharmaceutical industry to expand access to advanced biologic therapies for pediatric populations that have historically been underserved.
Phase 3 Studies Support Regulatory Review
Advertisement
The FDA submission is supported by data from two randomized, double-blind, multicenter Phase 3 pediatric clinical trials evaluating ENTYVIO in patients between the ages of 2 and 17 years. The KEPLER study assessed efficacy and safety in pediatric ulcerative colitis, while the ongoing WEBB study is evaluating the therapy in pediatric Crohn’s disease. The primary endpoint in the KEPLER trial focused on clinical remission at Week 54 among patients achieving a response following induction therapy, while the WEBB study includes co-primary endpoints of clinical remission and endoscopic response.
These studies represent some of the most comprehensive investigations of vedolizumab in pediatric IBD conducted to date. Beyond the United States, Takeda has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency, with additional regulatory filings planned in other markets later this year. The global regulatory strategy reflects growing confidence in the therapy’s potential to meet important unmet needs in pediatric gastroenterology.
Expanding Access to Precision Biologic Therapies
ENTYVIO has become one of the most widely used biologic treatments for inflammatory bowel disease, with approvals in more than 80 countries and over 1.9 million patient-years of global exposure. The therapy’s gut-focused mechanism differentiates it from many systemic immunosuppressive treatments and has contributed to its widespread adoption in adult IBD care. Expanding its indication into pediatric populations would represent a major advancement in precision medicine approaches for gastrointestinal disorders, providing clinicians with an additional evidence-based option to manage chronic inflammation while minimizing broader immune system effects.
As rates of pediatric ulcerative colitis and Crohn’s disease continue to increase globally, regulatory progress for innovative therapies such as ENTYVIO is expected to play a crucial role in improving long-term disease outcomes, quality of life, and treatment accessibility for young patients. Takeda’s latest FDA milestone therefore represents not only a regulatory achievement but also a potential turning point in pediatric inflammatory bowel disease management worldwide.
Source: Takeda press release
